Shares of PureTech Health plc (OTCMKTS:PTCHF – Get Free Report) were up 0.1% on Monday . The stock traded as high as $2.75 and last traded at $2.75. Approximately 50,209 shares changed hands during mid-day trading, an increase of 44% from the average daily volume of 34,786 shares. The stock had previously closed at $2.75.
PureTech Health Price Performance
The business has a 50 day moving average price of $2.67 and a 200-day moving average price of $2.36.
PureTech Health Company Profile
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.
Featured Articles
- Five stocks we like better than PureTech Health
- What is a SEC Filing?
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Value Stocks You Can Buy Before They Become Big
- Most active stocks: Dollar volume vs share volume
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
